An investigation on the expression of miR-۳۴ and miR-۱۴۴ in plasma samples of RET-positive and RET-negative Medullar Thyroid Carcinoma patients

سال انتشار: 1399
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 236

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

CIGS16_385

تاریخ نمایه سازی: 14 اردیبهشت 1400

چکیده مقاله:

Background and Aim: Medullary Thyroid Carcinoma (MTC) is an uncommon malignant thyroid cancer, originating from parafollicular C cells. MTC can be manifested as an aggressive carcinoma with metastasis, especially in sporadic forms. RET proto-oncogene mutations occurs in all hereditary and some somatic MTCs, so detection of RET mutations is needed for prompt and appropriate treatment. MicroRNAs (miRNAs) are noncoding regulatory RNAs. Extensive studies have done in progress or suppression of several types of cancers such as MTCs with remarkable application as prognostic markers. Of the effective miRNAs in cancers, miR-۱۴۴ and miR-۳۴ were evaluated in our study.Methods: Blood samples of ۲۵ RET positive and ۲۵ RET negative Blood samples of MTC patients were evaluated for these miRNAs, using Real-time Polymerase Chain Reaction (Real-time PCR), and the results were analyzed by the ۲-ΔΔCt method, showing, miR-۳۴a and miR-۱۴۴ expression was relatively increased in MTC patients compared to normal control samples and also in RET positives versus RET negatives.Results: We recruited ۵۰ out of ۳۵۰ MTC plasma samples (۲۷ female and ۲۳ male) which were selected based on RET mutation in exon ۱۱ (۲۵ RET positive and ۲۵ RET negative), with a mean± SD age of ۳۷.۰۴ ± ۱.۷۴ years. Receiver Operating Characteristic (ROC) curve analysis was carried out to assess the prognostic value of these miRNAs; although, they showed no significant prognostic value as MTC biomarkers in plasma samples.Conclusion: In conclusion, miRNAs can be used as biomarkers of cancers such as MTC, but further studies are required to find the best candidate miRNAs for diagnosis of cancers.

نویسندگان

Noushin Shabani

PhD. Student, Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Mehdi Hedayati

PhD., Cellular and Molecular Endocrine Research Center (CMERC), Research Institute for Endocrine Sciences,Shahid Beheshti University of Medical Sciences, Tehran, Iran

Samira Mohammadi-Yeganeh

PhD., Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran